PRESS RELEASE

from Tissue Regenix Group PLC (NASDAQ:TRX )

Hardman & Co Research on Tissue Regenix (TRX): Turning profitable and cash-generative

Hardman & Co Research
Hardman & Co Research on Tissue Regenix (TRX): Turning profitable and cash-generative

05-Apr-2023 / 14:55 GMT/BST
The issuer is solely responsible for the content of this announcement.


Hardman & Co Research on Tissue Regenix (TRX):

Turning profitable and cash-generative

 

TRX is focused on the development and commercialisation of two proprietary processing technologies for the repair of soft tissue (dCELL®) and bone (BioRinse®). It has a broad portfolio of regenerative medicine products for the biosurgery, orthopaedics and dental markets. 2022 results highlighted the benefits from recent investment in capacity and commercialisation, with the company turning EBITDA-positive in 4Q’22. Further strong growth is expected in 2023, with TRX becoming cash-generative and nearing profitability. Additional operating efficiencies have been identified, moving Phase 2 of the capacity expansion programme into 2025.

 

Please click on the link below for the full report:

https://hardmanandco.com/research/corporate-research/turning-profitable-and-cash-generative/

If you are interested in meeting the company, you can register your interest by clicking on the above link

To contact us:

Hardman & Co
1 Frederick’s Place

London

EC2R 8AE

www.hardmanandco.com

Follow us on Twitter @HardmanandCo

Contact:

Martin Hall



+44(0)203 693 7075

 

mh@hardmanandco.com

 

Hardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement.

About Hardman & Co: Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259. Attention is drawn to the important disclaimers at the end of the report.



Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.


End of Announcement - EQS News Service

1602355  05-Apr-2023 

fncls.ssp?fn=show_t_gif&application_id=1602355&application_name=news&site_id=symex
See all Tissue Regenix Group PLC news